LupusTrials.org Archives - Page 4 of 16

Category: LupusTrials.org

Encouraging Results with Obinutuzumab for Lupus Nephritis

February 13, 2022 The LRA is pleased to share a recently published paper reporting that the drug, obinutuzumab, showed positive results as a potential treatment for lupus nephritis in the phase 2 clinical trial NOBILITY. A medicine designed to attach a type of blood cell called B-cells with the marker CD20 on its surface, obinutuzumab […] Read More

Jane Salmon, MD – Determined to Help Pregnant Women Triumph Over Lupus

March 24, 2022 Recognized for her contributions to lupus during 2022’s Women’s History Month, Dr. Jane Salmon chose to specialize in lupus research because it was there that she felt she could be of greatest value. “There were so many unknowns in lupus with all its complexity. Here was a disease primarily affecting young women […] Read More

Lupus Research Alliance and Lupus Therapeutics Response to Positive Data from Phase 2 Study on Potential First-in-class Lupus Treatment

June 1, 2022 The Lupus Research Alliance (LRA) and its clinical trial arm Lupus Therapeutics congratulate Bristol Myers Squibb (BMS) on new positive results from a Phase 2 trial of its investigational agent deucravacitinib for the treatment of systemic lupus erythematosus (SLE). Deucravacitinib is a potentially first-in-class inhibitor of Tyrosine kinase 2 (TYK2), which regulates […] Read More

Positive Results on Anifrolumab for Lupus Published in New England Journal of Medicine

December 18, 2019 The Lupus Research Alliance (LRA) welcomes additional positive results published today in the New England Journal of Medicine online edition from AstraZeneca’s Phase 3 TULIP-2 trial studying the investigational biologic anifrolumab as a treatment for systemic lupus erythematosus (SLE or lupus). The new study provides further details showing that anifrolumab, which targets […] Read More

2018 LRA Lupus Insight Prize Recipient Receives $15 M Grant from NIH to Study Lupus Effects on the Brain

July 27, 2020 The Lupus Research Alliance congratulates 2018 Lupus Insight Prize recipient Betty Diamond, MD and the Feinstein Institutes for Medical Research on being awarded $15 million from the National Institute of Allergy and Infectious Disease to study brain dysfunction linked to lupus. Dr. Diamond will use the five-year grant to study a receptor […] Read More

Judith James, MD, PhD Fulfills Childhood Dream to be a Doctor with Outstanding Career in Lupus Treatment and Research

March 14, 2022 Dr. Judith James has wanted to be a doctor since she was four years old. But it wasn’t until she met two teenage lupus patients in the ICU that she determined to specialize in lupus treatment and research. “Both girls were 19; I was 19; one lived and one died. I was […] Read More

Baricitinib Development as a Lupus Treatment Discontinued

January 28, 2022 The Lupus Research Alliance is disappointed that the Phase 3 development program of OLUMIANT® (baricitinib) as a potential treatment for adults with systemic lupus erythematosus (SLE) has been discontinued. The drug’s manufacturer Lilly made this decision based on results from two Phase 3 trials (SLE-BRAVE-I and II). While SLE-BRAVE-I showed a significant […] Read More

FDA Authorizes Evusheld Emergency Use to Prevent COVID-19 in Immunocompromised Patients

December 9, 2021 People with lupus can be immunocompromised because of the disease itself or medications that suppress the immune system and some may not be adequately protected from COVID-19. A new treatment will soon be available for them. Evusheld was granted Emergency Use Authorization for COVID-19 prevention by the U.S. Food and Drug Administration […] Read More

Aurinia Announces Positive Long-Term Results on Lupykinis™ for Lupus Nephritis

December 9, 2021 The LRA is pleased to share positive topline three-year efficacy and safety results reported today by Aurinia Pharmaceuticals from the AURORA 2 continuation study of Lupkynis™ (voclosporin). These results provide the longest available data for an FDA-approved medicine in lupus nephritis. The U.S. Food and Drug Administration approved Lupkynis arlier this year […] Read More

Promise of Additional Lupus Therapies Highlighted at ACR 2021 Annual Meeting

November 9, 2021 Results of clinical trials testing many existing and potential lupus treatments were highlighted at the American College of Rheumatology’s annual meeting ACR Convergence 2021, November 3-9. Bringing you the most relevant news for our lupus community, following are summaries of key research presented at the meeting: New Data on Approved Lupus Treatments […] Read More